Domestic Business Driven FY17 Topline Growth Is Not Sustainable

105 Views07 May 2018 18:39

Daiichi Sankyo Co Ltd (4568 JP)'s FY17 results Domestic pharma performance (up ~7% y-o-y to ¥613b and contribution up 400bps to 64% of total sales...

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 4-minute read)

Discussions

(Paid Plans Only)

Asia Healthcare Analyst

Pathology Associates Limited

Japan & ChinaHealth CareEquity Bottom-Up

Price Chart(Sign Up to Access)

Insight Stream